Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vermillion CEO Gail Page to step down

This article was originally published in Clinica

Executive Summary

Diagnostics specialist Vermillion has started looking for a successor to president and CEO Gail Page after announcing that she will leave the company. The firm, which is seeking new leadership for its commercial phase of development, hopes to find a replacement by September. Ms Page has led Vermillion since 2004; during this time, the firm has seen its OVA1 ovarian cancer blood test approved by the US FDA (www.clinica.co.uk, 16 September 2009) and launched by partner Quest Diagnostics (www.clinica.co.uk, 10 March 2010). She was also "fundamental" in developing the relationship with Quest, and helped Vermillion raise over $110m in funding. Ms Page has resigned from the board of directors, but will continue to head up the company until her successor is found.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098936

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel